Nosaki, Kaname

Publications

Sort by

Co-Author Network

selected publications

Protocol summary of a randomized phase III study: comparing systemic therapy with and without debulking surgery (primary tumour resection) for clinical stage IVA (cT1-2bN0-1M1a) non-small cell lung cancer with radiologically undetermined pleural dissemination JCOG2103 (DEBULK-LUNG). Japanese journal of clinical oncology. 2024 Academic Article GET IT
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia. Lung cancer (Amsterdam, Netherlands). 2024 Academic Article GET IT
Clinical significance of a prospective large genomic screening for small-cell lung cancer: the genetic classification and a biomarker driven phase II trial of gedatolisib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2024 Academic Article GET IT
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Academic Article GET IT
Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50]. 2024 GET IT
Unrealistic expectations and disclosure of incurability in patients with non-small cell lung cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2024 Academic Article GET IT
Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study. International journal of clinical oncology. 2024 Academic Article GET IT
Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia. Lung cancer (Amsterdam, Netherlands). 2024 Academic Article GET IT
Times cited: 4
Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer. The oncologist. 2024 Academic Article GET IT
Times cited: 3
Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation. Lung cancer (Amsterdam, Netherlands). 2023 Academic Article GET IT
Times cited: 2
Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2023 Academic Article GET IT
Times cited: 7
Prognostic impact and gene expression analysis of peri-tumoral alveolar macrophage in resected lung adenocarcinoma. Cancer science. 2023 Academic Article GET IT
Times cited: 2
A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid). Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Editorial Article GET IT
Times cited: 1
Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma. Cancer immunology, immunotherapy : CII. 2023 Review GET IT
Times cited: 3
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. Lung cancer (Amsterdam, Netherlands). 2023 Academic Article GET IT
Times cited: 1
Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study. Lung cancer (Amsterdam, Netherlands). 2022 Academic Article GET IT
Times cited: 15
The impact of tertiary lymphoid structures on clinicopathological, genetic and gene expression characteristics in lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands). 2022 Academic Article GET IT
Times cited: 15
Prognostic Awareness and Discussions of Incurability in Patients with Pretreated Non-Small Cell Lung Cancer and Caregivers: A Prospective Cohort Study. The oncologist. 2022 Academic Article GET IT
Times cited: 8
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). Journal for immunotherapy of cancer. 2022 Academic Article GET IT
Times cited: 30
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. Nature. 2021 Academic Article GET IT
Times cited: 42
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. Cancer science. 2021 Academic Article GET IT
Times cited: 4
Comparison of the efficiency of endobronchial ultrasound-guided transbronchial needle aspiration using a 22G needle versus 25G needle for the diagnosis of lymph node metastasis in patients with lung cancer: a prospective randomized, crossover study. Translational lung cancer research. 2021 Academic Article GET IT
Times cited: 6
High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung. Lung cancer (Amsterdam, Netherlands). 2021 Academic Article GET IT
Times cited: 2
Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study. Thoracic cancer. 2021 Academic Article GET IT
Times cited: 20
The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment. Cancer medicine. 2021 Academic Article GET IT
Times cited: 6
Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2021 Academic Article GET IT
Times cited: 12
A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L). Clinical lung cancer. 2021 Academic Article GET IT
Times cited: 3
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. Cancer science. 2020 Academic Article GET IT
Times cited: 16
Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. JTO clinical and research reports. 2020 Review GET IT
Times cited: 15
Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer. Journal of cancer research and clinical oncology. 2020 Academic Article GET IT
Times cited: 2
Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101). The oncologist. 2020 Academic Article GET IT
Times cited: 17
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study. Trials. 2020 Academic Article GET IT
Times cited: 4
Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. Lung cancer (Amsterdam, Netherlands). 2019 Academic Article GET IT
Times cited: 8
Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab. Journal of thoracic disease. 2019 Academic Article GET IT
Times cited: 338
[Ⅱ.Management of Immune Related Adverse Events Associated with Immune Checkpoint Inhibitors]. Gan to kagaku ryoho. Cancer & chemotherapy. 2019 Academic Article GET IT
Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients. Thoracic cancer. 2019 Academic Article GET IT
Times cited: 5
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung cancer (Amsterdam, Netherlands). 2019 Review GET IT
Times cited: 134
The Influence of Clinical T Factor on Predicting Pathologic N Factor in Resected Lung Cancer. The Annals of thoracic surgery. 2019 Academic Article GET IT
Times cited: 6
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. International journal of clinical oncology. 2019 Guideline GET IT
Times cited: 107
Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. The oncologist. 2019 Academic Article GET IT
Times cited: 17
Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer. Anticancer research. 2019 Academic Article GET IT
Times cited: 1
Pneumonectomy after induction chemoradiotherapy for locally advanced non-small cell lung cancer: should curative intent pulmonary resection be avoided?. Surgery today. 2019 Academic Article GET IT
Times cited: 5
Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. Cancer science. 2018 Academic Article GET IT
Times cited: 22
Is prophylactic cranial irradiation (PCI) needed in patients with extensive-stage small cell lung cancer showing complete response to first-line chemotherapy?. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2018 Review GET IT
Times cited: 13
Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study. Oncotarget. 2018 Academic Article GET IT
Times cited: 34
A case of different EGFR mutations in surgically resected synchronous triple lung cancer. 2018 GET IT
Times cited: 5
A typical carcinoid tumor of the lung presenting with pure persistent ground-glass opacity on high-resolution computed tomography: a case report. Surgical case reports. 2017 Academic Article GET IT
Times cited: 64
Surgical resection of a well-differentiated inflammatory liposarcoma of the middle mediastinum: a case report. 2017 GET IT
Times cited: 2
Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer. Cancer science. 2017 Academic Article GET IT
Times cited: 36
Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations. Oncotarget. 2017 Academic Article GET IT
Times cited: 66
Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type. Oncology letters. 2017 Academic Article GET IT
Times cited: 10
Uncommon features of surgically resected ALK-positive cavitary lung adenocarcinoma: a case report. Surgical case reports. 2017 Academic Article GET IT
Times cited: 616
The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma. Clinical lung cancer. 2017 Academic Article GET IT
Times cited: 26
Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 63
Pulmonary Resection for Synchronous M1b-cStage IV Non-Small Cell Lung Cancer Patients. The Annals of thoracic surgery. 2016 Academic Article GET IT
Times cited: 12
A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity. Molecular therapy oncolytics. 2016 Academic Article GET IT
Times cited: 36
The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma. Anticancer research. 2016 Academic Article GET IT
Times cited: 7
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. Lung cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
Times cited: 114
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Investigational new drugs. 2016 Academic Article GET IT
Times cited: 52
c-kit mutation-positive advanced thymic carcinoma successfully treated as a mediastinal gastrointestinal stromal tumor: A case report. Molecular and clinical oncology. 2016 Academic Article GET IT
Times cited: 8
Are Anthracycline-Based Regimens Truly Indicated To Be the Standard Chemotherapy Regimen for Thymic Carcinoma?. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Academic Article GET IT
Times cited: 10
The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer. Current treatment options in oncology. 2015 Academic Article GET IT
Times cited: 30
How should we manage small focal pure ground-glass opacity nodules on high-resolution computed tomography? A single institute experience. Surgical oncology. 2015 Academic Article GET IT
Times cited: 18
Influence of the distance between home and the hospital on patients with surgically resected non-small-cell lung cancer. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2015 Academic Article GET IT
Times cited: 5
Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib. 2015 GET IT
Times cited: 49
Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer. Surgery today. 2015 Academic Article GET IT
Times cited: 5
Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer. Oncology letters. 2015 Academic Article GET IT
Times cited: 5
Preoperative concurrent chemoradiotherapy followed by extrapleural pneumonectomy for patients with non-small cell lung cancer with malignant pleural effusion and/or pleural nodules: Ten-year results of a prematurely terminated single institute phase II trial. Surgical oncology. 2015 Academic Article GET IT
Times cited: 11
Role of surgical resection for patients with limited disease-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2015 Academic Article GET IT
Times cited: 59
Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib. 2014 GET IT
Times cited: 58
Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma. Anticancer research. 2014 Academic Article GET IT
Times cited: 8
Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. Cancer chemotherapy and pharmacology. 2013 Academic Article GET IT
Times cited: 77
Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance. Surgery today. 2013 Academic Article GET IT
Times cited: 27
LKB1 mutations frequently detected in mucinous bronchioloalveolar carcinoma. Japanese journal of clinical oncology. 2011 Academic Article GET IT
Times cited: 14
Signet ring cell adenocarcinoma of the lung with an EML4-ALK fusion gene mimicking mucinous (colloid) adenocarcinoma: a case report. 2011 GET IT
Times cited: 4
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors. Archives of drug information. 2011 Academic Article GET IT
Times cited: 19
Incidentally proven pulmonary "ALKoma". 2010 GET IT
Times cited: 5

more ...

less ...

Background

education and training

Ph.D., Kyushu University (Japan) 2017
M.D., Kyushu University Faculty of Medicine (Japan) 2005

Contact

full name

Kaname Nosaki

primary email

kan4007@med.cornell.edu

VIVO Weill Cornell Medical College

Kaname Nosaki Postdoctoral Associate in Cardiothoracic Surgery

Publications

selected publications

Background

education and training

Contact

full name

primary email